Correction to: Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence

Andrea Marie Ibrahim(Ottawa Hospital), Michael Ong(Ottawa Hospital), Horia Marginean(Ottawa Hospital), Dominick Bossé(Dana-Farber Cancer Institute), Carolyn Nessim(University of Ottawa), Melanie Le May(University of Ottawa), Xinni Song
Annals of Surgical Oncology
May 22, 2020
10.1245/s10434-020-08618-z
Cited by 1

Related Papers

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2021|392
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
|Journal for ImmunoTherapy of Cancer|2018|267
Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group
|Annals of Surgical Oncology|2021|251